ALX Oncology Holdings Inc.
General ticker "ALXO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $55.0M (TTM average)
ALX Oncology Holdings Inc. follows the US Stock Market performance with the rate: 31.2%.
Estimated limits based on current volatility of 4.7%: low 1.22$, high 1.34$
Factors to consider:
- Total employees count: 80 (+11.1%) as of 2024
- Top business risk factors: Significant losses, Dependence on lead product, Clinical trial uncertainties, High cost and complexity of clinical trials, Regulatory and compliance
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.92$, 3.27$]
- 2025-12-31 to 2026-12-31 estimated range: [0.78$, 2.52$]
Financial Metrics affecting the ALXO estimates:
- Positive: with PPE of -0.7 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 97.37 > -0.66
- Positive: Shareholder equity ratio, % of 76.89 > 63.39
- Positive: Interest expense per share per price, % of 1.95 <= 3.41
- Negative: Operating cash flow per share per price, % of -137.63 <= 0.33
Short-term ALXO quotes
Long-term ALXO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $127.44MM | $170.28MM | $142.47MM |
| Operating Income | $-127.44MM | $-170.28MM | $-142.47MM |
| Non-Operating Income | $4.02MM | $9.47MM | $7.62MM |
| Interest Expense | $0.24MM | $1.56MM | $1.73MM |
| R&D Expense | $98.40MM | $141.79MM | $116.37MM |
| Income(Loss) | $-123.42MM | $-160.81MM | $-134.85MM |
| Taxes | $0.06MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-123.48MM | $-160.81MM | $-134.85MM |
| Stockholders Equity | $263.46MM | $189.71MM | $113.62MM |
| Assets | $306.49MM | $242.55MM | $147.78MM |
| Operating Cash Flow | $-89.22MM | $-130.36MM | $-121.91MM |
| Capital expenditure | $1.43MM | $1.27MM | $0.45MM |
| Investing Cash Flow | $-235.42MM | $44.66MM | $86.26MM |
| Financing Cash Flow | $9.86MM | $59.29MM | $30.82MM |
| Earnings Per Share** | $-3.03 | $-3.74 | $-2.58 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.